Horn, D.B
It changes how we think about treatment
Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the receptor every GLP-1 compound binds), MC4R (a melanocortin receptor central to satiety), and TCF7L2 (tied to glucose handling and GLP-1 secretion) describe the metabolic terrain a clinician prescribes into
Ultimately, the ability to donate plasma is a testament to your good health and generosity
The tracker allows patients to self-identify, provide their location, and say which brand of GLP-1 drug they are not able to find
Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects